This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Syneron Medical's CEO Discusses Q4 2011 Results - Earnings Call Transcript

Syneron Medical Ltd. ( ELOS)

Q4 2011 Earnings Call

February 9, 2012 8:30 am ET


Dr. Shimon Eckhouse – Chairman

Louis Scafuri – Chief Executive Officer

Asaf Alperovitz – Chief Financial Officer


Anthony Vendetti – Maxim Group

Dalton Chandler – Needham & Co.

Jeremy Feffer – Cantor Fitzgerald

Richard Newitter – Leerink Swann



Good day ladies and gentlemen and welcome to the Syneron Medical Fourth Quarter 2011 Results conference call. At this time, all participants are in a listen-only mode. Later we’ll conduct a question and answer session and instructions will follow at that time. If anyone should require assistance, please press star then zero on your touchtone telephone. As a reminder, this conference is being recorded.

I would now like to turn the call over to your host, Zach Kubow. Please go ahead, sir.

Zack Kubow – The Ruth Group

Thank you, Operator. I’d like to welcome everyone to Syneron Medical’s Fourth Quarter 2011 conference call, which will also cover the Company’s acquisition of Ultrashape that was announced yesterday. Statements on this call may be forward-looking within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 relating to the Company’s future events or future performance, including statements with respect to Syneron’s expectations regarding but not limited to the financial forecast for 2012, the launch of new products, the acquisition and integration of Ultrashape, and the maintenance of a leadership position in core and non-core markets.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs